英文論文 2014年度
- Soeda, H.，Shimodaira, H.，Watanabe, M.，Suzuki, T.，Gamo, M.，Takahashi, M.，Komine, K.，Kato, S.，Ishioka, C. KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment. Mol Clin Oncol 2: 356-362 (2014)
- Soeda, H.，Shimodaira, H.，Gamoh, M.，Ando, H.，Isobe, H.，Suto, T.，Takahashi, S.，Kakudo, Y.，Amagai, K.，Mori, T.，Watanabe, M.，Yamaguchi, T.，Kato, S.，Ishioka, C. Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801). Oncology 87: 7-20 (2014)
- Shiono, M.，Takahashi, S.，Kakudo, Y.，Takahashi, M.，Shimodaira, H.，Kato, S.，Ishioka, C. Upper arm central venous port implantation: a 6-year single institutional retrospective analysis and pictorial essay of procedures for insertion. PLoS One 9: e91335 (2014)
- Imai, H.，Kato, S.，Sakamoto, Y.，Kakudo, Y.，Shimodaira, H.，Ishioka, C. High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H. Oncol Rep 31: 1043-50 (2014)
- Shiono, M.，Kobayashi, T.，Takahashi, R.，Ueda, M.，Ishioka, C.，Hino, O. Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality. Sci Rep 4: 5927 (2014)
- Oda, A.，Saijo, K.，Ishioka, C.，Narita, K.，Katoh, T.，Watanabe, Y.，Fukuyoshi, S.，Takahashi, O. Predicting the structures of complexes between phosphoinositide 3-kinase (PI3K) and romidepsin-related compounds for the drug design of PI3K/histone deacetylase dual inhibitors using computational docking and the ligand-based drug design approach. J Mol Graph Model 54: 46-53 (2014)
- Komine, K.，Inoue, M.，Otsuka, K.，Fukuda, K.，Nanjo, H.，Shibata, H. Utility of measuring circulating tumor cell counts to assess the efficacy of treatment for carcinomas of unknown primary origin. Anticancer Res 34: 3165-8 (2014)
